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(599.9–831.2) vs. 583.0 (411.7–752.6) pg/ml, p < 0.001] 
and did not change c-FGF-23 concentration [70.5 (49.8–
103.3) vs. 77.1 (60.5–109.1) RU/ml, p = 0.9]. Simultane-
ously, alterations in bone turnover markers were observed. 
Serum concentration of CTX increased [0.49 (0.4–0.64) 
vs. 0.59 (0.46–0.85) ng/ml, p = 0.001], while bALP and 
TRAP 5b decreased [23.6 (18.8–31.4) vs. 17.9 (15.0–22.0) 
U/l, p < 0.0001 and 3.3 (3.0–3.7) vs. 2.8 (2.3–3.2) U/l, 
p < 0.001, respectively].
Conclusions Nephrectomy among patients with preserved 
renal function before surgery does not increase c-FGF-
23 but reduces sKL. Moreover, nephrectomy results in 
derangements in bone turnover markers in short-term fol-
low-up. These changes may participate in pathogenesis of 
bone disease after nephrectomy.
Keywords Acute GFR decline · Nephrectomy · Klotho · 
FGF-23 · Bone metabolism
Introduction
Fibroblast growth factor 23 (FGF-23) and Klotho are key 
players in maintaining mineral homoeostasis. Increase in 
FGF-23 concentration is accompanied by Klotho reduc-
tion as chronic kidney disease (CKD) worsens [1, 2]. Both 
molecules have gained attention for their association with 
important clinical outcomes such as cardiovascular inci-
dents [3] and mortality [4]. It has been thought that FGF-23 
and Klotho may link bone mineral disturbances with car-
diovascular mortality.
Recently, it was shown that among patients with acute 
kidney injury (AKI), FGF-23 concentrations are elevated 
and associated with negative clinical outcomes [5, 6]. In 
contrast, there is little data on FGF-23 and soluble Klotho 
Abstract 
Background  Increased concentration of fibroblast growth 
factor 23 (FGF-23) and decreased levels of soluble Klotho 
(sKL) are linked to negative clinical outcomes among 
patients with chronic kidney disease and acute kidney 
injury. Therefore, it is reasonable to hypothesize that GFR 
reduction caused by nephrectomy might alter mineral 
metabolism and induces adverse consequences. Whether 
nephrectomy due to urological indications causes derange-
ments in FGF-23 and sKL has not been studied. The aim of 
the study was to evaluate the effect of acute GFR decline 
due to unilateral nephrectomy on bone metabolism, FGF-
23 and sKL levels.
Methods This is a prospective, single-centre observational 
study of patients undergoing nephrectomy due to urologi-
cal indications. Levels of C-terminal FGF-23 (c-FGF-23), 
sKL and bone turnover markers [β-crosslaps (CTX), bone-
specific alkaline phosphatase (bALP) and tartrate-resistant 
acid phosphatase 5b (TRAP 5b)] were measured before and 
after surgery (5 ± 2 days).
Results Twenty-nine patients were studied (14 females, 
age 63.0 ± 11.6, eGFR 87.3 ± 19.2 ml/min/1.73 m2). 
After surgery, eGFR significantly declined (p < 0.0001). 
Nephrectomy significantly decreased sKL level [709.8 
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(sKL) after mild-to-moderate reduction in glomerular fil-
tration rate (GFR), which is evoked by nephrectomy. This 
might be especially important with regard to living kid-
ney donation and patients undergoing nephrectomy due 
to urological indications in light of negative connotations 
between FGF-23 and clinical consequences.
It is a matter of debate whether and how acute GFR 
decline predisposes to bone metabolism disturbances. The 
impact of those changes on bone metabolism has been 
studied in two groups of patients: living kidney donors 
and patients undergoing nephrectomy. On the one hand, 
nephrectomy due to renal cell carcinoma is a significant 
risk for osteoporosis and increased fracture risk [7], but, 
on the other hand, data concerning living kidney donors 
are conflicting. It is reported that even though living kid-
ney donors experience alterations of hormones involved in 
bone metabolism [8–10], there is no increased fracture risk 
[11]. The precise mechanism by which acute GFR decline 
predisposes to bone metabolism disturbances is largely 
unknown.
A nephrectomy due to urological indications in patients 
with preserved renal function offers unique clinical model 
to study effect of acute mild-to-moderate GFR decline, as 
the patients serve as their own controls without any con-
founding factors always present among patients with CKD 
and even more pronounced in AKI setting.
Regarding the fact that alterations in FGF-23 and 
sKL disturb bone health early in the course of CKD, the 
study was undertaken to evaluate the effect of acute GFR 
decline due to unilateral nephrectomy on bone metabolism, 
FGF-23 and sKL levels. The secondary aim was to assess 
whether changes in the concentration of the above mol-
ecules evoked by nephrectomy are associated with altera-
tions in the markers of bone formation and/or resorption.
Materials and methods
Study design
This study is a post hoc analysis of frozen blood and urine 
samples from the previously reported data [12]. The for-
mer study was designed as a prospective, single-centre 
trial and patient served as a self-control group. All patients 
undergoing nephrectomy due to urological indications 
in the Department of Oncological and General Urology, 
Sniadecki Provincial Hospital in Bialystok (Poland), were 
enrolled unless end-stage renal disease requiring dialysis 
(four patients) or lack of informed consent (five patients) 
was present.
After the surgery, all the patients underwent standard 
hydration protocol with isotonic saline. During the first 
24 h, 2500 ml of intravenous fluid was administered and nil 
per os was prescribed; on the second day, 1000 ml of intra-
venous fluid was given and patients were allowed to start 
progressive fluid oral intake. From the third day, no intrave-
nous fluids were given.
The study was approved by the local ethics committee. 
The protocol adhered to the principles of the Declaration of 
Helsinki and written informed consent was obtained from 
each participant.
Laboratory measurements
Urine and venous fasting blood samples were collected 
on the morning prior to surgery and after nephrectomy 
(5 ± 2 days after nephrectomy depending on the duration 
of hospitalization). To prevent possible changes due to 
intra-day variability, our samples were collected always at 
early morning, after overnight fasting. Plasma, serum and 
urine were centrifuged, aliquoted and frozen at −70 °C 
until assayed.
Serum soluble Klotho and plasma C-terminal FGF-23 
(c-FGF-23) levels were measured using the enzyme-linked 
immunosorbent assay (ELISA) kit (IBL, International 
GmbH, Hamburg, Germany; intra-assay CV < 4% and 
Immutopics, Inc., San Clemente, CA, USA; intra-assay 
CV < 2.5%, respectively). Serum bone-specific alkaline 
phosphatase (bALP) was determined by an ELISA kit from 
MicroVue (Quidel Corporation, San Diego, CA, USA; 
intra-assay CV < 6%). Tartrate-resistant acid phosphatase 
5b (TRAP 5b) was measured in serum by an ELISA kit 
from MicroVue (Quidel Corporation, San Diego, CA, 
USA; intra-assay CV < 2.2%). ELISA immunoassay was 
used to measure serum cross-linked C-telopeptide of type 
1 collagen (CTX, CrossLaps, IDS Nordic A/S, Herlev, 
Denmark; intra-assay CV < 6%). Plasma intact PTH lev-
els were measured using Immutopics assay (Inc., San Cle-
mente, CA, USA). All samples were assayed according to 
manufacturer’s recommendations. For sKL, samples were 
diluted two times. Blood and urine levels of creatinine, cal-
cium and phosphate were determined with standard labora-
tory methods.
Calculations and statistics
To estimate phosphate and calcium renal handling, we used 
the ratio of tubular maximum reabsorption to the glomeru-
lar filtration rate (TmPO4/eGFR—as an index for the phos-
phate renal threshold) and urinary fractional excretion of 
calcium (FECa). The calculations were made as follows:
TmPO4/eGFR = PO4 * (1 − FePO4) if FePO4 ≥ 0.2 oth-
erwise TmPO4/eGFR = PO4 * e (10.318 * Fe2PO4 − 5.1
8 * FePO4 + 0.4), where urinary fractional excretion of 
phosphate (FePO4) was computed as below:
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FePO4 = [(urinary phosphate × serum creatinine)/(serum 
phosphate × urinary creatinine)] [13, 14],
and FECa = [(urinary calcium × serum creatinine)/
(serum calcium × urinary creatinine)] × 100%.
GFR was estimated using CKD epidemiology collabora-
tion (CKD-EPI) equation [15].
Variable distribution was tested with the Shapiro–Wilk W 
test of normality. The normally distributed data were presented 
as mean ± 1 SD, the skewed data as median (interquartile 
range; IQR). Before statistical computations, logarithmic trans-
formations were performed on skewed variables to obtain nor-
mal distribution, if possible. Student’s t test for paired samples 
or Wilcoxon signed-rank test was used to compare continuous 
variables at selected time points. Changes in measured param-
eters were expressed as delta (∆) and calculated as follows: 
postoperative minus preoperative value. Associations between 
deltas were assessed using bivariate correlations with Pearson 
or Spearman’s test depending on meeting the assumptions. 
Mixed regression analyses accounting for time effect were per-
formed in search for longitudinal associations between varia-
bles of interest. Results were reported as beta coefficient β and 
95% confidence intervals (95% CI). A two-tailed p value of 
<0.05 was considered statistically significant. All computations 
were performed with Statistica 12 (StatSoft, Tulsa, OK, USA).
Results
Characteristics of the study population
We enrolled twenty-nine patients (14 females) who 
underwent nephrectomy. The mean baseline eGFR was 
87.3 ± 19.2 ml/min/1.73 m2. Additional baseline charac-
teristics of the studied population are detailed in Table 1. 
After nephrectomy in four subjects anuria occurred, thus 
parameters evaluated in urine were measured in 25 sub-
jects. In these patients, hydration protocol was violated, as 
they received fluids according to their condition. Statistical 
computations were repeated after exclusion of these cases 
and yielded similar results. None of the patients required 
dialysis during the study duration.
Groups with partial and radical nephrectomy and with 
tumour and non-tumour did not differ significantly con-
cerning evaluated parameters except from non-significant 
difference in baseline value of sKL between tumour and 
non-tumour group (tumour group—680.2 ± 131.2 vs. non-
tumour group—805.3 ± 185.9, p = 0.05).
Effect of nephrectomy on calcium, phosphate and iPTH
Biochemical parameters before and after nephrectomy 
are presented in Table 2. As expected, eGFR declined 
significantly after surgery compared with the baseline 
values (87.3 ± 19.2 vs. 69.8 ± 24.7 ml/min/1.73 m2, 
p < 0.0001). We observed significant decline in serum 
calcium and phosphate concentration (p < 0.0001 
and p = 0.002, respectively), while urinary calcium 
(p = 0.02) and phosphate excretion (reduction in TmPO4/
eGFR, p = 0.001) increased. There was no significant 
change in intact PTH concentration during the study 
period.
Phosphatemia changes [∆P = −0.54 (−1.01 to 0.11) 
mmol/l] were positively associated with ∆iPTH [∆ = 0.21 
(−0.44 to 0.92) pmol/l; r = 0.6, p = 0.002] and ∆c-FGF-23 
[∆ = 3.0 (−15.49 to 26.29) RU/ml; r = 0.6, p = 0.0001]. 
Phosphate level was determined by c-FGF-23 [β = 1.68 
(95% CI 0.82–2.53), p < 0.001], iPTH [β = 0.41 (95% CI 
0.08–0.74), p = 0.016] in mixed regression analysis model 
after adjustment for time effect and kidney function.
Alterations in serum calcium evoked by nephrectomy 
(∆Ca = −0.15 ± 0.15 mmol/l) were associated negatively 
with iPTH alterations (∆iPTH) (r = −0.4, p = 0.03) but 
not with any evaluated parameters. Serum calcium level 
was associated only with iPTH [β = −0.44 (95% CI −0.78 
to (−0.10)), p = 0.013] in mixed model adjusted for time 
effect and renal function.
Effect of nephrectomy on c‑FGF‑23, sKL
There was a significant decrease in sKL level (p < 0.0001) 
after nephrectomy (Fig. 1a). Serum concentration of 
c-FGF-23 was not changed by the procedure (Fig. 1b).
Alterations of c-FGF-23 concentration (∆c-FGF-23) 
were associated with ∆P (r = 0.6, p = 0.0001) and ∆eGFR 
(∆ = −17.45 ± 19.62 ml/ml/1.73 m2; r = −0.4, p = 0.04).
Table 1  Baseline characteristics of the study population
Data are mean ± SD or number (percentage)
Characteristic Value
Age (years) 63.0 ± 11.6
 Sex
 Male 15 (52%)
 Female 14 (48%)
Nephrectomy
 Partial 8 (28%)
 Radical 21 (72%)
Indication for nephrectomy
 Tumour 21 (72%)
 Cirrhotic kidney 4 (14%)
 Complex renal cysts 2 (7%)
 Kidney stones 1 (3.5%)
 Pyonephrosis 1 (3.5%)
 eGFR, ml/min/1.73 m2 87.3 ± 19.2
684 Int Urol Nephrol (2017) 49:681–688
1 3
Mixed regression analyses adjusted for time effect, renal 
function, and iPTH showed phosphate [β = 0.24 (95% CI 
0.12–0.36), p < 0.001] to be determinant of c-FGF-23 level.
Change in sKL [∆sKL = −148.6 (−237.1 to −56.8) 
pg/ml] was negatively associated with ∆CTX [∆ = 0.18 
(0.01–0.27) ng/ml; rho = −0.4, p = 0.03] and ∆iPTH 
(r = −0.6, p = 0.001).
Level of sKL remained significantly associated with 
iPTH (β = −0.47 [95% CI −0.70 to (−0.23)], p < 0.001) 
and CTX [β = −0.39 (95% CI −0.68 to (−0.09)), 
p = 0.013] after adjustment for renal function in mixed 
regression analysis.
Effect of nephrectomy on markers of bone resorption 
and formation
Nephrectomy resulted in alterations of bone turnover mark-
ers. Serum CTX increased after surgery compared to base-
line (p < 0.01; Fig. 2a), while serum TRAP 5b and bALP 
concentration decreased (p < 0.001; Fig. 2b and p < 0.0001; 
Fig. 2c).
Neither ∆CTX, ∆TRAP 5b nor ∆bALP correlated 
with ∆eGFR. ∆CTX evoked by nephrectomy was nega-
tively associated only with changes in sKL concentration 
(rho = −0.4, p = 0.03) and with alterations of serum phos-
phate (rho = 0.4, p = 0.04). In mixed regression model 
accounting for time effect, none of aforementioned param-
eters significantly predicted CTX concentration.
Changes of any evaluated parameters were not associ-
ated with bALP (∆bALP) and TRAP 5b (∆TRAP 5b) 
alterations.
Discussion
The aim of this study was to test the hypothesis, whether 
nephrectomy changes the concentration of c-FGF-23, 
sKL and affects bone metabolism. Our data show that 
acute reduction in GFR after nephrectomy does not alter 
c-FGF-23 concentration in short-term follow-up. It is in 
line with recent study performed in living kidney donors, 
which showed rather FGF-23 reduction but not the increase 
in short term [8]. On the other hand, we are aware that 
decrease in calcium concentration, observed in our study, 
might prevent FGF-23 increase, as was shown previously 
[16]. However, we did not observe any association between 
calcium and FGF-23 changes. These results are in con-
trast to data obtained from patients with AKI, in whom 
elevated FGF-23 levels are observed already after 1-h of 
AKI onset, with more than tenfold rise at 24 h [5]. Moreo-
ver, in human study it was shown that FGF-23 increase, at 
the end of cardiac surgery predicted AKI development [6]. 
The mechanisms underlying augmented FGF-23 levels in 
patients with AKI are unknown. Our data shed some light 
on potential mechanism, as it shows there are two possible 
explanations. Either there must be a threshold of acute GFR 
decline beyond which FGF-23 production escalates or there 
is a different factor involved, associated with acute state in 
the setting of AKI, activating FGF-23 increase.
Currently two assays measuring FGF-23 levels are avail-
able. Intact FGF-23 (iFGF-23) assay that detect only a bio-
logically active form and second one, used in our study, an 
assay measuring both c-terminal fragments and intact form 
of FGF-23. Thus, if intact form of FGF-23 is elevated then 
the c-terminal assay also would detect the rise. Of course 
when c-terminal assay detects elevation in FGF-23 it is dif-
ficult to say if there is a rise in iFGF-23 or increase in FGF-
23 cleavage. Since we did not observe any changes in c-ter-
minal FGF-23 assay, we can hypothesize that in our study 
neither no increased synthesis, nor degradation occurred. 
However, without c-FGF-23/iFGF-23 ratio to support our 
opinion, an alternative explanation is possible. Theoreti-
cally, no change in c-terminal FGF-23 measurement could 
Table 2  Changes in biochemical parameters after nephrectomy
Data are presented as number (percentage), mean ± SD or median 
(interquartile range)
eGFR estimated glomerular filtration rate, iPTH intact parathyroid 
hormone, c-FGF-23 c-terminal fibroblast growth factor 23, CTX 
cross-linked C-telopeptide of type 1 collagen, bALP bone-specific 
alkaline phosphatase, TRAP 5b tartrate-resistant acid phosphatase 5b, 
FECa urinary fractional excretion of calcium, TmPO4/eGFR ratio of 
tubular maximum reabsorption rate to the glomerular filtration rate
a For creatinine, data are presented as the median (min–max)





87.3 ± 19.2 69.8 ± 24.7 p < 0.001
Creatinine (mg/
dl)a
0.82 (0.56–1.7) 1.02 (0.58–6.28) p < 0.001
Calcium (mmol/l) 2.31 ± 0.11 2.17 ± 0.15 p < 0.001
Phosphate 
(mmol/l)
1.14 ± 0.2 0.97 ± 0.24 p = 0.002










70.5 (49.8–103.3) 77.1 (60.5–109.1) p = 0.9
CTX (ng/ml) 0.49 (0.4–0.64) 0.59 (0.46–0.85) p = 0.001
bALP (U/l) 23.6 (18.8–31.4) 17.9 (15.0–22.0) p < 0.001
TRAP 5b (U/l) 3.3 (3.0–3.7) 2.8 (2.3–3.2) p < 0.001
FECa (%) 0.67 (0.33–0.85) 1.14 (0.59–1.38) p = 0.02
TmPO4/eGFR 
(mmol/l)
1.07 (0.84–1.35) 0.8 (0.64–0.93) p = 0.001
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be due to decrease in intact and an increase in c-terminal 
FGF-23 fragments. Although already published data where 
both forms of FGF-23 were measured during AKI [5, 6, 
17], universally showed increase in c-FGF23 as well as 
iFGF-23. Thus, we believe that our data add interesting 
point to the discussion regarding mutual relations between 
acute GFR decrease and FGF-23 behaviour in different 
clinical settings. Even though our sample size was small, 
it provided approximately 80% power to detect at least 
































































Fig. 2  Impact of nephrectomy on serum levels of a cross-linked C-telopeptide of type 1 collagen (CTX), b tartrate-resistant acid phosphatase 5b 
(TRAP 5b) and c bone-specific alkaline phosphatase (bALP). Data are presented as median and interquartile range
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level, based on power calculations based on two previously 
published data (for iFGF-23 after nephrectomy [18], and 
c-FGF-23 after hip replacement procedure [19]).
Whether nephrectomy induces FGF-23 increase with 
all its negative consequences is especially important for 
living kidney donors. Data from kidney donors showed 
that in long-term follow-up after nephrectomy, FGF-23 
increases [9, 10, 18]. These results differ from those of our 
study, although we investigated short-term changes and our 
study population were patients with urological indications 
for nephrectomy. We may hypothesize that the increase in 
FGF-23 occurs at higher GFR decrease than observed in 
our study or our follow-up was relatively too short to detect 
changes. A rise in FGF-23 is an effect of GFR decline, and 
time is essential for those changes to become evident.
Our finding that FGF-23 levels are constant, despite 
nephrectomy is especially interesting in the context of 
results obtained by Goebel et al., who reported significant 
increase in FGF-23 after orthopaedic procedures [19]. 
It points that rather other stimuli than surgery by itself 
induces this molecule’s production. This hypothesis is in 
line with data obtained in animal experiment where sham-
operated rats FGF-23 levels were stable [20]. Results from 
ICU patients, where FGF-23 increase was observed despite 
normal renal function, make the question about factors 
determining FGF-23 levels even more intriguing [21].
In agreement with previous reports [22], we observed a 
significant decrease in serum sKL after renal mass reduc-
tion, reaffirming the statement that kidneys are the major 
source of sKL. Study in living kidney donors with longer 
follow-up demonstrated that sKL increased after the initial 
postoperative reduction but still was lower than pre-dona-
tion [8]. Apart from Klotho’s role in ageing and phosphate 
homoeostasis [23], its soluble form acts as an endocrine 
protein that exerts pleiotropic actions, including protec-
tion of endothelial function by its antioxidant properties, 
inhibition of vascular calcification, suppression of fibrosis 
and inflammation [24, 25]. Reduced sKL may therefore 
contribute to many complications but how it translates to 
any patient-oriented measures is still a matter of debate. 
Even though sKL is discussed as a novel biomarker for 
progression in CKD [26], there are conflicting data from 
human studies regarding influence of sKL levels on clini-
cal outcomes, reporting both positive [27] as well as neutral 
effects [28]. Acute reduction in GFR resulted in derange-
ments in minerals handled by the kidneys, e.g., decreased 
serum calcium and phosphate levels. The most probable 
cause of reduction in phosphate concentration was increase 
in renal losses. Our data showed also increased calcium 
fractional excretion after nephrectomy. Even though 
decreased serum calcium is connected to disturbed vita-
min D metabolism [29], hypocalcemia may not be specific 
only to nephrectomy, since hypocalcemia and secondary 
increase in PTH were observed after different abdomi-
nal surgeries [30]. In our opinion, hypercalciuria may be 
partly caused by sKL reduction, as lack of this molecule 
diminishes the activity of TRPV5 channels [31] and leads 
to increased renal calcium excretion although we did not 
observe significant association between the degree of cal-
ciuria and magnitude of sKL reduction.
Another compelling finding of the present study is that 
an acute decline in GFR, caused by nephrectomy, is associ-
ated with the alterations in both markers of bone metabo-
lism: resorption and formation. We have shown in our study 
the rise in CTX and decrease in bALP and TRAP 5b after 
nephrectomy. This finding seems to be conflicting as CTX 
and TRAP 5b are both markers of resorption, and we have 
found their opposite behaviour after surgery. Since CTX 
tends to accumulate as the renal function declines [32, 33], 
TRAP 5b, which is degraded in the liver, is more accurate 
in our study population, because kidney function has no 
effect on circulating TRAP 5b activity [34, 35].
Our study suggests that surgically induced nephron loss 
leads to decrease in bone turnover, which could disintegrate 
bone homoeostasis. Although we are aware that due to 
short-term evaluation in our study, one may speculate that 
reported changes are rather the effects of the surgery but 
not renal mass reduction. However, after hip replacement 
surgery, one week after procedure, no changes in serum cal-
cium, phosphorus, total alkaline phosphatase and urinary 
phosphorus were reported [36]. Based on current sparse 
data from human [36] and animal studies [20], it seems that 
rather nephrectomy but not the surgery induces changes 
in bone metabolism. Broader impact of the changes initi-
ated by nephrectomy is unclear. Animal work shows that 
subtotally nephrectomized rats had alterations of the struc-
tural and mechanical properties of cortical bone material 
[37]. Human data reported by Bagrodia et al. [7] revealed 
the association of radical nephrectomy with higher risk of 
postoperative osteoporosis and fractures, showing the supe-
riority of partial over radical nephrectomy. On the other 
hand, in the study of kidney donors, the fracture rate was 
not significantly higher compared to controls [11], although 
others reported disturbances in bone metabolism markers 
[10]. Further studies concerning this matter are needed. If 
the association between nephrectomy and disturbed bone 
metabolism is confirmed in a larger study, prevention of 
changes in bone health might become important concern in 
management of kidney donors and urological patients.
There are some limitations of this study. We are aware 
that there is a difficulty in assessment parameters changes 
after nephrectomy, caused by the possible influence of the 
fasting before operation, undergoing anaesthesia and intra-
venous hydration. However, at least with regard to c-FGF-
23, recently published study showed that acute volume 
changes do not impact its measurements [38]. The study 
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population consisted of patients with various indications for 
nephrectomy; therefore, we cannot exclude that the pres-
ence of different diseases had an impact on our conclusions. 
Since our results were uniform and each patient served as 
their own control, it seems very unlikely although cannot 
be ruled out. Moreover, our aim was to evaluate the impact 
of the nephrectomy on FGF-23 and sKL concentrations in 
patients with preserved renal function; nevertheless, we did 
not study living kidney donors. Thus, our study’s findings 
might not be relevant to this specific group. Additional study 
with longer follow-up is needed to confirm that our results 
are consistent over the time. However, we think that this 
study makes interesting point in the discussion about FGF-
23 short-term behaviour after kidney injury, showing that 
nephrectomy may differ from other types of kidney damage.
The study was not designed to examine patients’ out-
comes, which does not allow for conclusions regarding 
causality. Finally, the comparator group and assessing the 
degree of bone loss by a bone mineral density technique 
would undoubtedly strengthen our results.
In summary, we present data showing neutral effect of 
GFR reduction on FGF-23 concentration of patients under-
going nephrectomy due to urological indications. Evoked 
reduction in renal mass causes decrease in sKL level. 
Whether it translates to patient-oriented clinical outcomes 
requires further investigation. Moreover, nephrectomy 
resulted in derangements in bone turnover markers. These 
changes may participate in pathogenesis of bone disease 
after nephrectomy.
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